OSE 2101

Drug Profile

OSE 2101

Alternative Names: EP-2101; IDM 2101; OSE-2101; Tedopi

Latest Information Update: 23 Sep 2016

Price : $50

At a glance

  • Originator IDM Pharma
  • Developer OSE Immunotherapeutics
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Breast cancer; Colorectal cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 31 May 2016 Effimune has merged with OSE Pharma to form OSE Immunotherapeutics
  • 09 Mar 2016 Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Italy (SC) (NCT02654587)
  • 01 Jan 2016 Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom, Spain, Poland, Hungary, Germany (SC) after January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top